Relevance of CYP3A5 Expression on the Clinical Outcome of Patients With Renal Cell Carcinoma

被引:2
|
作者
Matsumoto, Jun [1 ]
Kotera, Yumi [1 ]
Watari, Shogo [2 ]
Takeuchi, Koichi [1 ]
Ueki, Hideo [2 ]
Koyama, Toshihiro [3 ]
Wada, Koichiro [2 ]
Fujiyoshi, Masachika [1 ]
Nasu, Yasutomo [2 ]
Ariyoshi, Noritaka [1 ]
机构
[1] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Personalized Med & Prevent Healthcare Sci, Okayama, Japan
[2] Okayama Univ, Grad Sch Med Dent Pharmaceut Sci, Dept Urol, Okayama, Japan
[3] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Pharmaceut Biomed, Okayama, Japan
关键词
human; cytochrome P450 CYP3A; renal cell carcinoma treatment outcome; CYTOCHROME-P450; 3A; OVARIAN-CANCER; IDENTIFICATION; RESISTANCE; ISOFORM; LIVER; RAT;
D O I
10.21873/anticanres.15029
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background/Aim: This study aimed to elucidate the detailed characteristics of CYP3A5 expression and the association between CYP3A5 expression and clinical outcomes in patients with renal cell carcinoma (RCC). Patients and Methods: This study retrospectively enrolled 124 Japanese patients with RCC treated at the Okayama University Hospital. The commonest CYP3A5 gene polymorphism, CYP3A5*3, and expression levels of CYP3A5 mRNA and protein in each tissue were examined. Results: Expression of CYP3A5 mRNA and protein in RCC tissues was significantly down-regulated compared to that in adjacent normal tissues. High level of CYP3A5 mRNA expression significantly extended cancer-specific survival (p=0.004) and overall survival (p=0.002). The CYP3A5 mRNA expression level was identified as a significant independent prognostic factor for both cancer-specific survival and overall survival. Conclusion: CYP3A5 could serve as a potential marker for prognostication and treatment planning for patients with RCC.
引用
收藏
页码:2511 / 2521
页数:11
相关论文
共 50 条
  • [1] Clinical Relevance of CYP3A5 Genotype on Maraviroc Exposures
    Vourvahis, Manoli
    Mcfadyen, Lynn
    Heera, Jayvant
    Clark, Andrew
    DRUG METABOLISM AND DISPOSITION, 2015, 43 (05) : 771 - 772
  • [2] CYP3A5 and ABCB1 Polymorphisms as Predictors for Sunitinib Outcome in Metastatic Renal Cell Carcinoma
    Diekstra, Meta H. M.
    Swen, Jesse J.
    Boven, Epie
    Castellano, Daniel
    Gelderblom, Hans
    Mathijssen, Ron H. J.
    Rodriguez-Antona, Cristina
    Garcia-Donas, Jesus
    Rini, Brian I.
    Guchelaar, Henk-Jan
    EUROPEAN UROLOGY, 2015, 68 (04) : 621 - 629
  • [3] CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.
    Diekstra, Meta
    Swen, Jesse J.
    Boven, Epie
    Castellano, Daniel E.
    Gelderblom, Hans
    Mathijssen, Ron H. J.
    Rodriguez-Antona, Cristina
    Garcia-Donas, Jesus
    Rini, Brian I.
    Guchelaar, Henk-jan
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] Response to "Clinical Relevance of CYP3A5 Genotype on Maraviroc Exposures"
    Lu, Yanhui
    Fuchs, Edward J.
    Hendrix, Craig W.
    Bumpus, Namandje N.
    DRUG METABOLISM AND DISPOSITION, 2015, 43 (05) : 773 - 773
  • [5] Possible impact of CYP3A4 and CYP3A5 genotypes on carbamazepine metabolism and clinical outcome in epileptic patients
    Magliulo, L.
    Viana, M.
    Fallarini, S.
    Scordo, M. Gabriella
    Dahl, Marja-Liisa
    Monaco, Francesco
    Lombardi, Grazia
    FEBS JOURNAL, 2010, 277 : 289 - 290
  • [6] Influence of CYP3A5 Polymorphism in Donor and Recipient on Tacrolimus Pharmacokinetics and Clinical Outcome after Renal Transplantation
    Cauffiez, Christelle
    Glowacki, Francois
    Lionet, Arnaud
    Provot, Francois
    Hazzan, Marc
    Noel, Christian
    Allorge, Delphine
    Broly, Franck
    THERAPEUTIC DRUG MONITORING, 2009, 31 (05) : 661 - 661
  • [7] INFLUENCE OF CYP3A5 POLYMORPHISM IN DONOR AND RECIPIENT ON TACROLIMUS PHARMACOKINETICS AND CLINICAL OUTCOME AFTER RENAL TRANSPLANTATION
    Cauffiez, Christelle
    Glowacki, Francois
    Lionet, Arnaud
    Provot, Francois
    Hazzan, Marc
    Noel, Christian
    Broly, Franck
    TRANSPLANT INTERNATIONAL, 2009, 22 : 174 - 174
  • [8] Dosing Tacrolimus Based on CYP3A5 Genotype: Will It Improve Clinical Outcome?
    van Gelder, T.
    Hesselink, D. A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 (06) : 640 - 641
  • [9] CYP3A5 EXPRESSION IN HUMAN ENTEROCYTES
    JANARDAN, SK
    LOWN, KS
    GHOSH, M
    KOLARS, JC
    WATKINS, PB
    GASTROENTEROLOGY, 1994, 106 (04) : A241 - A241
  • [10] Frequencies of the CYP3A5*3 variant in renal transplant patients in Northern Portugal
    Lima, Carla
    Peixoto, Maria
    Dias, Manuel
    Alves, Helena
    TISSUE ANTIGENS, 2010, 75 (05): : 589 - 590